Skip to main navigation Skip to search Skip to main content

Pembrolizumab plus axitinib versus sunitinib monotherapy as firstline treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial (vol 21, p1563, 2020)

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Pembrolizumab plus axitinib versus sunitinib monotherapy as firstline treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial (vol 21, p1563, 2020)'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science